EHS
EHS

Price of alirocumab would have to be cut to be cost-effective



(HealthDay)—For patients with a recent acute coronary syndrome receiving a statin, the price of alirocumab would have to be reduced to be cost-effective, according to a study published online Jan. 1 in the Annals of Internal Medicine.

Source link

EHS
Back to top button